FDA staff scrutinizes new hot-flash remedies

Staffers at the FDA weighed in new drugs from Depomed and Hisamitsu Pharmaceutical for combating post-menopausal hot flashes, saying that the drugs showed efficacy while raising no new red flags on safety, Reuters reported. Depomed shares spiked yesterday as the company races with Hisamitsu to garner the first FDA approvals of non-hormonal drugs for tempering hot flashes, even though Depomed's drug fell short of efficacy goals in trials. Article